Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Glioblastoma
IDH-wildtype disease that almost always recurs: EGFR, the blood-brain barrier and cell therapy attempts.
ESMO Congress 2026
23–27 Oct 2026, Madrid · Annals of Oncology, vol. 37 supplement
The ESMO 2026 abstract supplement was not in Crossref on 11 Nov 2026 and ESMO's congress platform blocks automated access, so ESMO abstracts here come from web research: each row was found on a published congress report and verified against it.
Headline and verified abstracts
21 abstracts found by Parallel web research on 2026-11-11 and verified: 21 against the saved source excerpt. Rows that could not be verified were dropped. Titles and metadata only; abstract text is not stored.
- 692OOral presentation
- 693OOral presentation
- 694OOral presentation
- 695RORapid oral
- 121PPosterMRI radiomics-guided drug reversal analysis for therapeutic vulnerability mapping in glioblastomaYuzuha KadookaMatches source excerptcslide.ctimeetingtech.com
- 704PPoster
- 706PPosterIvonescimab combined with dose-dense temozolomide in recurrent glioblastoma: Preliminary results of efficacy and safety from a single-arm, phase Ib/II trialLi YanchuivonescimabtemozolomideMatches source excerptcslide.ctimeetingtech.com
- 707PPosterTeniposide plus cisplatin or carboplatin in recurrent high-grade glioma: Pre-planned interim analysis of an ongoing multicenter, open-label, single-arm trialBohao Zhang (presented by Wenbin Li)teniposidecisplatincarboplatinMatches source excerptcslide.ctimeetingtech.com
- 709PPosterEarly metabolic response and seizure control with vorasidenib in IDH-mutant gliomas: Real-world results from the VORAFET studyVORAFETvorasidenibMatches source excerptcslide.ctimeetingtech.com
- 710PPoster
- 712PPoster
- 713PPoster
- 714PPoster
- 716PPoster[68Ga]Ga-anti-integrin peptide for imaging αvβ3 in glioblastomaJuliana Carron (presented by Carmen S. Passos Lima)[68Ga]Ga-anti-integrin peptideMatches source excerptcslide.ctimeetingtech.com
- 717PPosterPrognostic and therapeutic implications of routine NGS in IDHwt high-grade gliomasMathieu LarroquetteMatches source excerptcslide.ctimeetingtech.com
- 718ePPoster
- 727TiPPoster
- 730ePPoster
- 739ePPosterReal-world efficacy and safety of vorasidenib in IDH-mutant grade 2 gliomas: A multicenter study from SpainvorasidenibMatches source excerptcslide.ctimeetingtech.com
- 765ePPosterDiagnostic and treatment pathway experience in primary brain tumours: A cross-sectional analysisJuan Manuel Sepulveda SanchezMatches source excerptcslide.ctimeetingtech.com
- 771ePPosterCDKN2A-altered gliomas: Real-world outcomes across subtypes from the RETSINE/GEINO registryEstela Pineda (presented by Sonia Del Barco)temozolomidebevacizumabMatches source excerptcslide.ctimeetingtech.com
Indexed in Crossref
The ESMO Congress 2026 supplement (Annals of Oncology, vol. 37 supplement) was not in Crossref when last checked on 11 Nov 2026. The verified abstracts above come from web research instead.